Podium to Practice: Chicago 2025 – GI: MATTERHORN

Podium to Practice: Chicago 2025 – GI: MATTERHORN

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Sharlene Gill

Icon Chair Speaker

Speakers

Dr. Rachel Goodwin

Dr. Florian Lordick

Studies / Trials Discussed

LBA5 – Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).

Studies/trials discussed:

LBA5 – Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).
Tagged